Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for GLAXO
Revenue projections for GLAXO

Revenues for GLAXO are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 1.790000
forwardPE 47.461094
debtToEquity 0.510000
earningsGrowth 0.352000
revenueGrowth 0.048000
grossMargins 0.622890
operatingMargins 0.330730
trailingEps 54.660000
forwardEps 57.900000

GLAXO's current ratio of 1.79 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, GLAXO can comfortably cover its liabilities, reflecting a strong financial outlook.
GLAXO's positive gross and operating margins highlight its profitability and operational efficiency. These strong margins demonstrate the company's ability to control costs while generating substantial revenue, contributing to a healthy financial performance.
GlaxoSmithKline Pharmaceuticals Limited's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that GlaxoSmithKline Pharmaceuticals Limited is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for GLAXO
Price projections for GLAXO

GlaxoSmithKline Pharmaceuticals Limited's price projections have consistently been revised higher, indicating growing confidence in the company's future potential. Analysts appear more optimistic about GlaxoSmithKline Pharmaceuticals Limited's ability to generate strong results going forward.

Recommendation changes over time:

Recommendations trend for GLAXO
Recommendations trend for GLAXO


Analysts have provided no decisive buy or sell ratings for GLAXO, offering a mixed view of the stock's future. This lack of clarity suggests that investors should look at a wider range of indicators before forming an opinion on whether to invest.